BACKGROUND: Major depression occurs in 4.4% to 20% of the general population. Studies
suggest that major depression is accompanied by immune dysregulation and activation of …

Background: Cholinesterase inhibitors (ChEIs) are the only drugs marketed for the treatment
of Alzheimer's disease. Despite numerous randomized controlled trials, the efficacy and …

Objective To conduct a systematic review and meta‐analysis of studies that measured cytokine
and chemokine levels in individuals with major depressive disorder ( MDD ) compared to …

Objectives To quantify and compare potential benefits (subjective reports of sleep variables)
and risks (adverse events and morning-after psychomotor impairment) of short term …

… Author links open overlay panel Krista L. Lanctôt a b c , Luis Agüera-Ortiz d e , Henry … ,
potential biomarkers include the precursor l-3,4-dihydroxyphenylalanine (L-DOPA), dopamine (DA…

Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing
substantial distress for both people with dementia and their caregivers, and contributing to early …

… : Krista L Lanctôt (co-primary author) has received research support from AbbVie and Pfizer;
and consultation fees from AbbVie, Lundbeck, Merck, and Otsuka, in addition to grants from …

The behavioral and psychological symptoms of dementia (BPSD) can have serious debilitating
effects on the patient and increase caregiver burden. Investigations into the underlying …

Alzheimer's disease (AD) is characterized by disruptions in multiple major neurotransmitters.
While many studies have attempted to establish whether GABA is disrupted in AD patients, …

Mounting evidence suggests that aberrations in immune-inflammatory pathways contribute
to the pathophysiology of major depressive disorder (MDD), and individuals with MDD may …